U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C34H38N3O7P
Molecular Weight 631.6552
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EFONIDIPINE

SMILES

CC1=C(C(C2=CC=CC(=C2)[N+]([O-])=O)C(=C(C)N1)P3(=O)OCC(C)(C)CO3)C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5

InChI

InChIKey=NSVFSAJIGAJDMR-UHFFFAOYSA-N
InChI=1S/C34H38N3O7P/c1-24-30(33(38)42-19-18-36(28-15-9-6-10-16-28)21-26-12-7-5-8-13-26)31(27-14-11-17-29(20-27)37(39)40)32(25(2)35-24)45(41)43-22-34(3,4)23-44-45/h5-17,20,31,35H,18-19,21-23H2,1-4H3

HIDE SMILES / InChI

Molecular Formula C34H38N3O7P
Molecular Weight 631.6552
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Efonidipine is a 1,4-dihydropyridine derivative for the treatment of hypertension and angina. Efonidipine exerts its antihypertensive and antianginal effects through blocking L- and T-type calcium channels.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
13.0 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LANDEL
Primary
LANDEL

Cmax

ValueDoseCo-administeredAnalytePopulation
1.7 ng/mL
10 mg single, oral
EFONIDIPINE plasma
Homo sapiens
11.7 ng/mL
20 mg single, oral
EFONIDIPINE plasma
Homo sapiens
17.9 ng/mL
40 mg single, oral
EFONIDIPINE plasma
Homo sapiens
10.8 ng/mL
20 mg single, oral
EFONIDIPINE plasma
Homo sapiens
12.9 ng/mL
20 mg single, oral
EFONIDIPINE plasma
Homo sapiens
19.7 ng/mL
30 mg single, oral
EFONIDIPINE plasma
Homo sapiens
26.1 ng/mL
30 mg single, oral
EFONIDIPINE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
4.1 ng × h/mL
10 mg single, oral
EFONIDIPINE plasma
Homo sapiens
25.4 ng × h/mL
20 mg single, oral
EFONIDIPINE plasma
Homo sapiens
57.6 ng × h/mL
40 mg single, oral
EFONIDIPINE plasma
Homo sapiens
34.7 ng × h/mL
20 mg single, oral
EFONIDIPINE plasma
Homo sapiens
31.5 ng × h/mL
20 mg single, oral
EFONIDIPINE plasma
Homo sapiens
61.7 ng × h/mL
30 mg single, oral
EFONIDIPINE plasma
Homo sapiens
68.8 ng × h/mL
30 mg single, oral
EFONIDIPINE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
2.9 h
10 mg single, oral
EFONIDIPINE plasma
Homo sapiens
1.4 h
20 mg single, oral
EFONIDIPINE plasma
Homo sapiens
2.2 h
40 mg single, oral
EFONIDIPINE plasma
Homo sapiens
2 h
20 mg single, oral
EFONIDIPINE plasma
Homo sapiens
2.1 h
20 mg single, oral
EFONIDIPINE plasma
Homo sapiens
1.8 h
30 mg single, oral
EFONIDIPINE plasma
Homo sapiens
1.7 h
30 mg single, oral
EFONIDIPINE plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
0.2%
EFONIDIPINE serum
Homo sapiens

Doses

PubMed

Sample Use Guides

In Vivo Use Guide
40 mg once daily for 12 weeks
Route of Administration: Oral
In Vitro Use Guide
Effects of efonidipine on isolated myocardial and aortic preparations was studied. The drug produced concentration-dependent negative chronotropic effects on isolated guinea-pig atrial preparations.The potency was 3.08 x 10(-8)M (EC30).
Substance Class Chemical
Record UNII
40ZTP2T37Q
Record Status Validated (UNII)
Record Version